Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion description "[A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion evidence source_evidence_literature NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion SIO_000772 14604977 NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion wasDerivedFrom befree-2016 NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_assertion wasGeneratedBy ECO_0000203 NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.
- befree-2016 importedOn "2016-02-19" NP419711.RAdCFpu-J2__qs07jEPsQphRw__haRorQrThmuvD5l5DE130_provenance.